JP2017507931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507931A5 JP2017507931A5 JP2016550261A JP2016550261A JP2017507931A5 JP 2017507931 A5 JP2017507931 A5 JP 2017507931A5 JP 2016550261 A JP2016550261 A JP 2016550261A JP 2016550261 A JP2016550261 A JP 2016550261A JP 2017507931 A5 JP2017507931 A5 JP 2017507931A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- composition according
- agent
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020144077A JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2023126665A JP7767361B2 (ja) | 2014-02-05 | 2023-08-03 | がん及び感染症の治療方法並びに治療用組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936168P | 2014-02-05 | 2014-02-05 | |
| US61/936,168 | 2014-02-05 | ||
| PCT/US2015/014687 WO2015120198A1 (en) | 2014-02-05 | 2015-02-05 | Methods and compositions for treating cancer and infectious diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144077A Division JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017507931A JP2017507931A (ja) | 2017-03-23 |
| JP2017507931A5 true JP2017507931A5 (OSRAM) | 2018-03-08 |
Family
ID=53778458
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550261A Pending JP2017507931A (ja) | 2014-02-05 | 2015-02-05 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2020144077A Active JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2023126665A Active JP7767361B2 (ja) | 2014-02-05 | 2023-08-03 | がん及び感染症の治療方法並びに治療用組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144077A Active JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2023126665A Active JP7767361B2 (ja) | 2014-02-05 | 2023-08-03 | がん及び感染症の治療方法並びに治療用組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11213583B2 (OSRAM) |
| EP (1) | EP3102233B1 (OSRAM) |
| JP (3) | JP2017507931A (OSRAM) |
| CN (1) | CN105979961B (OSRAM) |
| CA (1) | CA2937035A1 (OSRAM) |
| WO (1) | WO2015120198A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| US8906374B2 (en) | 2010-04-20 | 2014-12-09 | Cedars-Sinai Medical Center | Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| WO2015120198A1 (en) | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| ES2808728T3 (es) * | 2014-02-21 | 2021-03-01 | Idac Theranostics Inc | Agente terapéutico para cáncer sólido |
| LT3116909T (lt) | 2014-03-14 | 2020-02-10 | Novartis Ag | Antikūno molekulės prieš lag-3 ir jų panaudojimas |
| CA2943834A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
| EP3156072B1 (en) * | 2014-06-11 | 2020-08-19 | IDAC Theranostics, Inc. | Method for reducing side effects of immune checkpoint control agent |
| BR112017004826A2 (pt) | 2014-09-13 | 2017-12-12 | Novartis Ag | terapias de combinação de inibidores de alk |
| EP3206711B1 (en) | 2014-10-14 | 2023-05-31 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| WO2016090219A1 (en) * | 2014-12-05 | 2016-06-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bromodomain inhibitor as adjuvant in cancer immunotherapy |
| EP3310384A1 (en) * | 2015-06-17 | 2018-04-25 | CureVac AG | Vaccine composition |
| AU2016308286B2 (en) | 2015-08-18 | 2022-04-07 | Rakuten Medical, Inc. | Phthalocyanine dye conjugates and their storage |
| CN119564879A (zh) * | 2015-08-18 | 2025-03-07 | 乐天医药生技股份有限公司 | 用于光免疫疗法的组合物、联用及相关方法 |
| AU2016329120B2 (en) | 2015-10-02 | 2023-04-13 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for a costimulatory TNF receptor |
| CN109476751B (zh) | 2016-05-27 | 2024-04-19 | 艾吉纳斯公司 | 抗tim-3抗体及其使用方法 |
| EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| EP3496707A4 (en) * | 2016-08-09 | 2020-03-25 | Angimmune, LLC | Treatment of cancer using a combination of immunomodulation and check point inhibitors |
| WO2018071500A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| EP3705124A4 (en) * | 2017-10-30 | 2021-07-14 | Ube Industries, Ltd. | PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH A SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND AN IMMUNOTHERAPEUTIC |
| KR102721494B1 (ko) * | 2018-04-17 | 2024-10-24 | 국립암센터 | 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도 |
| EP3856207A4 (en) * | 2018-09-27 | 2022-11-16 | Genocea Biosciences, Inc. | TREATMENT PROCESSES |
| KR102300846B1 (ko) * | 2019-11-01 | 2021-09-09 | 서울대학교산학협력단 | 면역 활성 개선용 조성물 및 이의 방법 |
| US20230076515A1 (en) * | 2019-11-18 | 2023-03-09 | Children's Medical Center Corporation | Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy |
| US20230075779A1 (en) * | 2020-01-30 | 2023-03-09 | Apeximmune Therapeutics Inc. | Methods and compositions for treating cancer or viral infection with a pla2g2d antagonist |
| CN113045661B (zh) | 2021-04-07 | 2022-06-21 | 中美冠科生物技术（太仓）有限公司 | 新型抗cd4抗体 |
| IL322401A (en) * | 2023-02-06 | 2025-09-01 | Gmp Biotechnology Ltd | MTOR therapies for cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| GB2302353B (en) | 1995-06-21 | 1998-11-11 | British Gas Plc | Method of filling an excavated opening |
| GB0217777D0 (en) | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
| NZ540555A (en) | 2002-11-15 | 2008-04-30 | Genmab As | Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders |
| EP1814568A4 (en) | 2004-10-29 | 2009-08-12 | Univ Southern California | COMBINATION IMMUNOTHERAPY AGAINST CANCER WITH COSTIMULATORY MOLECULES |
| US20090317407A1 (en) * | 2006-05-02 | 2009-12-24 | Lacelle Michael G | Augmentation of immune response to cancer vaccine |
| EP2032168A4 (en) | 2006-06-02 | 2010-12-29 | Ariad Pharma Inc | COMBINED THERAPY BASED ON CAPECITABINE |
| JP2009541338A (ja) | 2006-06-19 | 2009-11-26 | ワイス | Ｉｌ−２２およびｉｌ−１７の調節方法 |
| JP5399900B2 (ja) | 2006-06-30 | 2014-01-29 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｉｇｆｂｐ２インヒビター |
| CN102203132A (zh) * | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| PL2374883T3 (pl) * | 2008-12-26 | 2017-05-31 | Kyowa Hakko Kirin Co., Ltd. | Przeciwciało anty-CD4 |
| US20100196311A1 (en) | 2009-01-14 | 2010-08-05 | Kim Hyung L | METHODS AND COMPOSITIONS CONTAINING mTOR INHIBITORS FOR ENHANCING IMMUNE RESPONSES |
| WO2010124498A1 (en) | 2009-04-30 | 2010-11-04 | Beijing Cellonis Biotechnology Co., Ltd | A resistance-screened tumor stem cell, its antigen composition, an anti-tumor dendritic cell loading with said antigens, their preparation methods, uses and kits thereof as well as a dendritic cell vaccine |
| IL323000A (en) * | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| US8906374B2 (en) | 2010-04-20 | 2014-12-09 | Cedars-Sinai Medical Center | Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors |
| WO2011139738A2 (en) * | 2010-04-28 | 2011-11-10 | Tenx Biopharma, Inc. | Therapies using zanolimumab to enhance the immune response |
| CN103957939A (zh) | 2011-09-19 | 2014-07-30 | 约翰霍普金斯大学 | 癌症免疫治疗 |
| WO2015120198A1 (en) | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| RU2016146993A (ru) * | 2014-05-21 | 2018-06-21 | Пфайзер Инк. | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака |
| JP6274542B2 (ja) | 2014-12-02 | 2018-02-07 | 国立大学法人 東京大学 | 抗ｃｄ４抗体を有効成分とする抗がん剤の治療効果を判定する方法 |
-
2015
- 2015-02-05 WO PCT/US2015/014687 patent/WO2015120198A1/en not_active Ceased
- 2015-02-05 EP EP15747022.0A patent/EP3102233B1/en active Active
- 2015-02-05 US US15/116,485 patent/US11213583B2/en active Active
- 2015-02-05 CN CN201580007415.4A patent/CN105979961B/zh active Active
- 2015-02-05 JP JP2016550261A patent/JP2017507931A/ja active Pending
- 2015-02-05 CA CA2937035A patent/CA2937035A1/en active Pending
-
2020
- 2020-08-28 JP JP2020144077A patent/JP7328187B2/ja active Active
-
2021
- 2021-11-22 US US17/533,065 patent/US20220152198A1/en active Pending
-
2023
- 2023-08-03 JP JP2023126665A patent/JP7767361B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507931A5 (OSRAM) | ||
| JP2023133525A5 (OSRAM) | ||
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| US20230181605A1 (en) | Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity | |
| EP3407911B1 (en) | Methods and pharmaceutical composition for the treatment of cancer | |
| JP2017501167A5 (OSRAM) | ||
| US12377094B2 (en) | Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapies | |
| RU2017121096A (ru) | Комбинированная терапия, включающая применение ох40-связывающих агонистов и антагонистов связывания оси pd-1 | |
| JP2017537090A5 (OSRAM) | ||
| KR20180105685A (ko) | 투카레솔 또는 이의 유사체를 함유하는 조성물 | |
| KR20170137717A (ko) | 암의 치료를 위한 방법, 조성물, 및 키트 | |
| BRPI0717688A2 (pt) | mÉtodos para tratar neoplasma e mÉtodos para tratar neoplasma de plasmàcitos | |
| JP2019503387A5 (OSRAM) | ||
| US20220265823A1 (en) | Uses of myostatin antagonists, combinations containing them and uses thereof | |
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| WO2023240082A2 (en) | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer | |
| JP2023501209A (ja) | 白血病またはリンパ腫の治療のためのレナリドミドと組み合わせた抗ｃｄ１９療法 | |
| JP2024016209A (ja) | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ | |
| US20220025061A1 (en) | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist | |
| CN102935228B (zh) | 用于肿瘤治疗的试剂、其用途及方法 | |
| CN113573707A (zh) | 用于治疗癌症的组合产品 | |
| US20250034255A1 (en) | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer | |
| EP3008089A1 (en) | Combination of cd37 antibodies with chlorambucil | |
| WO2018227280A1 (en) | Therapeutic combinations comprising eosinophil-depleting antibodies and uses thereof | |
| WO2025190251A1 (zh) | 抗trop2抗体药物偶联物和pd-1拮抗剂联合治疗实体瘤的用途 |